DMAC DiaMedica Therapeutics
- 3.350
- +0.100+3.08%
DiaMedica Therapeutics News
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Lake Street Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating, Maintains Target Price $7
Craig-Hallum Reaffirms Their Buy Rating on Diamedica Therapeutics (DMAC)
Craig-Hallum Maintains DiaMedica Therapeutics(DMAC.US) With Buy Rating
Craig-Hallum Releases a Buy Rating on Diamedica Therapeutics (DMAC)
Diamedica Therapeutics (DMAC) Gets a Buy From Craig-Hallum
Diamedica Therapeutics (DMAC) Gets a Buy From Craig-Hallum
DiaMedica Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Inspire Medical Systems (INSP) and Maravai Lifesciences Holdings (MRVI)
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Gossamer Bio (GOSS) and Vor Biopharma (VOR)
DiaMedica Therapeutics Analyst Ratings
Analysts Conflicted on These Healthcare Names: Diamedica Therapeutics (DMAC), Design Therapeutics (DSGN) and MiMedx Group (MDXG)
Analysts' Top Healthcare Picks: Diamedica Therapeutics (DMAC), Abivax SA Sponsored ADR (ABVX)
Diamedica Therapeutics (DMAC) Gets a Buy From Craig-Hallum
Craig-Hallum Sticks to Their Buy Rating for Diamedica Therapeutics (DMAC)
Craig-Hallum Remains a Buy on Diamedica Therapeutics (DMAC)
Oppenheimer Upgrades DiaMedica Therapeutics to Outperform, Announces $7 Price Target
Analysts Are Bullish on These Healthcare Stocks: Fennec Pharmaceuticals (FENC), Diamedica Therapeutics (DMAC)
Analysis
Price Target
No Data
